Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.61 |
| ▸ | PPARG | P37231 | 3/20 | 0.61 |
| ▸ | FBP1 | P09467 | 9/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15546762 | 0.85 | POLB (0.49) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL197882 | 0.85 | PPARA (0.64) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL20730087 | 0.85 | PPARA (0.64) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL12670824 | 0.84 | PPARA (0.62) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL31357666 | 0.82 | PPARA (0.61) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL655568 | 0.82 | PPARA (0.61) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL421202 | 0.82 | PPARA (0.61) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL4422408 | 0.82 | PPARA (0.68) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL1417870 | 0.81 | PPARA (0.71) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL1549954 | 0.81 | PPARA (0.60) | PPARAPPARGFBP1ABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875001-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| CN-103570630-B | Nitrogen heterocyclic derivative and the application in medicine thereof | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2016-04-20 | — | — | CN | disclosed |
| EP-2875001-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-05-27 | — | — | EP | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| CN-103570630-A | Heterocyclic nitrogen derivative and application thereof in medicines | GUANGDONG HEC PHARMACEUTICAL | 2014-02-12 | — | — | CN | disclosed |
| WO-2014012360-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-01-23 | — | — | WO | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | PPARA 642/4885PPARG 2214/4885FBP1 691/4885 |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | PPARA 455/4885PPARG 396/4885FBP1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.